Home LiteratureArticle Details
PMID: 13678977 Published · ppublish English Comparative Study Journal Article Research Support, U.S. Gov't, P.H.S. Review

Tuberculosis.

Lancet (London, England) ·Vol. 362 ·No. 9387 ·2003-09-13 ·Pages 887-99

Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C

Abstract

Among communicable diseases, tuberculosis is the second leading cause of death worldwide, killing nearly 2 million people each year. Most cases are in less-developed countries; over the past decade, tuberculosis incidence has increased in Africa, mainly as a result of the burden of HIV infection, and in the former Soviet Union, owing to socioeconomic change and decline of the health-care system. Definitive diagnosis of tuberculosis remains based on culture for Mycobacterium tuberculosis, but rapid diagnosis of infectious tuberculosis by simple sputum smear for acid-fast bacilli remains an important tool, and more rapid molecular techniques hold promise. Treatment with several drugs for 6 months or more can cure more than 95% of patients; direct observation of treatment, a component of the recommended five-element DOTS strategy, is judged to be the standard of care by most authorities, but currently only a third of cases worldwide are treated under this approach. Systematic monitoring of case detection and treatment outcomes is essential to effective service delivery. The proportion of patients diagnosed and treated effectively has increased greatly over the past decade but is still far short of global targets. Efforts to develop more effective tuberculosis vaccines are under way, but even if one is identified, more effective treatment systems are likely to be required for decades. Other modes of tuberculosis control, such as treatment of latent infection, have a potentially important role in some contexts. Until tuberculosis is controlled worldwide, it will continue to be a major killer in less-developed countries and a constant threat in most of the more-developed countries.

MeSH Terms
Adolescent Adult Anti-HIV Agents/therapeutic use Antitubercular Agents/supply & distribution,therapeutic use BCG Vaccine/therapeutic use Breast Feeding Comorbidity Developing Countries/statistics & numerical data Female HIV Infections/drug therapy,epidemiology Humans Male Middle Aged Mycobacterium tuberculosis/isolation & purification Pregnancy Sputum/microbiology Tuberculosis/drug therapy,prevention & control Tuberculosis, Pulmonary/drug therapy,epidemiology,prevention & control
Chemicals
Anti-HIV Agents Antitubercular Agents BCG Vaccine
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Frieden Thomas R
New York City Department of Health and Mental Hygiene, New York, NY 10013, USA. tfrieden@health.nyc.gov
Sterling Timothy R
Munsiff Sonal S
Watt Catherine J
Dye Christopher
Article Info
Journal
Lancet (London, England)
Abbr.
Lancet
ISSN
1474-547X
Published
2003-09-13
Pages
887-99
Language
English
Region
England
NLM ID
2985213R
Subset
IM
Grants
NIAID NIH HHS · K23 AIO1654 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com